St. Jude Medical
This article was originally published in The Gray Sheet
Executive SummaryMechanical heart valve manufacturer announces it will continue a stock repurchase program authorized by its board of directors in July ("The Gray Sheet" July 20, 1992, p. 24). Under the program, the company may repurchase up to 5% of its outstanding common stock, or approximately 2.4 mil. of the roughly 48 mil. shares outstanding. Only 265,000 shares have been repurchased to date under the program. St. Jude President and CEO Ronald Matricaria says the continuation of the repurchase program stems from the firm's belief that its stock is "significantly undervalued." He notes that "anticipation of the Clinton Administration's reform proposals, coupled with the prospect of an increasingly competitive heart valve market, has resulted in a depression of our stock price".
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.